ArticleNature communications2025

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.

Chen Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.